Recently, VEGFRs peptide vaccines have been considered to hold the advantages of anti-angiogenic therapy and immunotherapy and have been extensively studied and tested in patients with progressive neurofibromatosis type 2 (NF2) (64), which also implies the potential of anti-angiogenic therapy in combination with other drugs in cancer therapy. Here, NF2 is linked to NF2-related schwannomatosis.